Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Aethlon Medical ( (AEMD) ).
On January 22, 2026, Aethlon Medical, Inc. and an institutional investor amended a December 5, 2025 Securities Purchase Agreement to remove a requirement that the company obtain shareholder approval under Nasdaq Rule 5635 before pre-funded warrants could be exercised, making those warrants immediately exercisable while leaving all other terms of the agreement unchanged. On the same date, the parties also amended a December 8, 2025 pre-funded common stock purchase warrant on identical terms, a move that accelerates the potential conversion of these instruments into common stock and could impact Aethlon Medical’s capital structure and existing shareholders’ dilution profile.
The most recent analyst rating on (AEMD) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Aethlon Medical stock, see the AEMD Stock Forecast page.
Spark’s Take on AEMD Stock
According to Spark, TipRanks’ AI Analyst, AEMD is a Neutral.
Overall score is weighed down primarily by very weak financial performance (minimal/zero revenue, large losses, and heavy cash burn). Technicals are mixed with only a short-term rebound against a longer-term downtrend, while valuation provides little support due to negative earnings. The earnings call adds a modest positive offset from cost reductions and clinical safety progress, but slow enrollment and cash runway concerns remain key risks.
To see Spark’s full report on AEMD stock, click here.
More about Aethlon Medical
Average Trading Volume: 123,876
Technical Sentiment Signal: Sell
Current Market Cap: $3.19M
For detailed information about AEMD stock, go to TipRanks’ Stock Analysis page.